The Experts below are selected from a list of 15357 Experts worldwide ranked by ideXlab platform

J. C. De Jongste - One of the best experts on this subject based on the ideXlab platform.

  • Daily Exhaled Nitric Oxide measurements and asthma exacerbations in children.
    Allergy, 2011
    Co-Authors: R. J. P. Van Der Valk, Eugenio Baraldi, Georgette Stern, Urs Frey, J. C. De Jongste
    Abstract:

    To cite this article: van der Valk RJP, Baraldi E, Stern G, Frey U, de Jongste JC. Daily Exhaled Nitric Oxide measurements and asthma exacerbations in children. Allergy 2012; 67: 265–271. Abstract Background:  Fractional Exhaled Nitric Oxide (FeNO) is a biomarker for eosinophilic airway inflammation and can be measured at home on a daily basis. A short-term increase in FeNO may indicate a higher risk of future asthma exacerbations. Objective:  To assess changes in FeNO before and after asthma exacerbations compared to a stable control period. Methods:  A post hoc analysis was performed on daily FeNO measurements over 30 weeks in children with asthma (n = 77). Moderate exacerbations were defined by an increase in symptom scores and severe exacerbations by prescription of prednisone. Individual mean and maximum FeNO, the variability of FeNO assessed by the coefficient of variation (CV), and slopes of FeNO in time were all quantified in 3-week blocks. Cross-correlation of FeNO with symptoms and autocorrelation of FeNO were assessed in relation to exacerbations and examined as predictors for exacerbations compared to reference periods using logistic regression. Results:  Fractional Exhaled Nitric Oxide could be assessed in relation to 25 moderate and 12 severe exacerbations. The CV, slope, cross-correlation, and autocorrelation of daily FeNO increased before moderate exacerbations. Increases in slope were also randomly seen in 19% of 2-week blocks of children without exacerbations. At least 3–5 FeNO measurements in the 3 weeks before an exacerbation were needed to calculate a slope that could predict moderate exacerbations. No specific pattern of FeNO was seen before severe exacerbations. Conclusion:  Fractional Exhaled Nitric Oxide monitoring revealed changes in FeNO prior to moderate exacerbations. Whether this can be used to prevent loss of asthma control should be further explored.

  • Environmental exposure in relation to Exhaled Nitric Oxide in newborns : is it all about timing? Smoke exposure, airway symptoms and Exhaled Nitric Oxide in infants: the Generation R study
    European Respiratory Journal, 2008
    Co-Authors: P. Latzin, Urs Frey, Carmelo Gabriele, R. Asgarali, Vincent W. V. Jaddoe, A. Hofman, Henriëtte A. Moll, J. C. De Jongste
    Abstract:

    The effect of pre- and post-natal smoke exposure on Exhaled Nitric Oxide fraction (FeNO) in infants was evaluated and the association between respiratory symptoms and FeNO in the first 2 months of life was investigated. The Generation R study is a population-based, prenatally recruited birth cohort. Exposures were assessed by means of questionnaires prospectively administered during pregnancy and after birth. Successful off-line FeNO measurements during tidal breathing were obtained in 187 infants (median age 6.9 weeks). The association between possible determinants and log FeNO was investigated with multiple linear regression analysis. Infants exposed pre- and post-natally to smoke showed lower FeNO than infants exposed only after birth (geometric mean difference (95% confidence interval) 1.5 (1.0-2.1) ppb) and never-exposed infants (1.4 (1.0-1.8) ppb). FeNO was reduced in infants with severe upper respiratory symptoms compared with infants with nonsevere symptoms (1.6 (1.0-2.4) ppb). Infants with symptoms of the lower respiratory tract had lower FeNO than asymptomatic infants (1.2 (1.0-1.50) ppb). In conclusion, the nature of the association between smoke exposure and Exhaled Nitric Oxide fraction is dependent on timing and intensity of exposure. The occurrence and the severity of respiratory symptoms in the first 2 months of life are associated with lower Exhaled Nitric Oxide fraction.

  • Measurement of Exhaled Nitric Oxide in children, 2001
    The European respiratory journal, 2002
    Co-Authors: Eugenio Baraldi, Hartmut Grasemann, J. C. De Jongste, Benjamin Gaston, Kjell Alving, Peter J. Barnes, Hans Bisgaard, Andrew Bush, C. Gaultier, John F. Hunt
    Abstract:

    Measurement of fractional Exhaled Nitric Oxide in Exhaled air is an exciting innovative technique that gives new insights in to the pathophysiology of lung disease and asthma in particular, with many potential clinical applications. Careful standardisation of measurement techniques will facilitate the use of this new measurement in paediatric respiratory medicine; this Task Force was set up for this purpose. Methodologies, for use in all age groups, are already available and there are abundant questions relating to interpretation and application of fractional Exhaled Nitric Oxide waiting to be addressed. Noninvasiveness and instantaneous results potentially make it a suitable monitoring instrument for use in children. Exhaled Nitric Oxide measurement has definitely found its way into clinical research in paediatric respiratory medicine. Evidence for clinically-useful applications is accumulating, and the merits of this new technique must now be demonstrated in larger studies, using standardised methodology in an appropriate setting.

Mona Torab Jahromi - One of the best experts on this subject based on the ideXlab platform.

  • The association between Exhaled Nitric Oxide and sleep apnea: the role of BMI.
    Respiratory medicine, 2014
    Co-Authors: Seyyed Jalilmirmohammadi, Amir Houshang Mehrparvar, Sara Safaei, Ehsan Samimi, Mona Torab Jahromi
    Abstract:

    Summary Background Obstructive sleep apnea syndrome is associated with airway inflammation. Measurement of Exhaled Nitric Oxide is a non-invasive method for evaluation of airway diseases. It seems that obesity is an exacerbating factor for airway inflammation. We aimed to evaluate the changes of Exhaled Nitric Oxide after sleep in patients suffering from OSA regarding BMI. Method In 54 patients referred for polysomnography, Exhaled Nitric Oxide measurements were performed before and after sleep. Subjects were divided into three categories: normal, obese with sleep apnea and non-obese, based on polysomnographic recordings and BMI. Results 47 subjects had abnormal apnea/hypopnea index (AHI mean = 39.7) and 7 were normal regarding AHI (AHI mean = 3.0). BMI was significantly correlated to AHI, number of desaturations and hypoxia. Among those with apnea, 31 subjects were obese and 16 were non-obese. Exhaled Nitric Oxide levels in normal and OSA subjects showed no significant change, but a significant increase was found in obese patients with apnea (14.7 pre-sleep mean, 20.0 post-sleep mean). Conclusions Obesity is an effective factor in the inflammation of airways in patients with obstructive apnea.

Andrew Mcivor - One of the best experts on this subject based on the ideXlab platform.

  • Update on Exhaled Nitric Oxide in pulmonary disease.
    Expert review of respiratory medicine, 2012
    Co-Authors: Naomi Spitale, Nooreen Popat, Andrew Mcivor
    Abstract:

    The ability to assess the inflammatory status of a patient’s airway using a noninvasive method is the ideal situation for clinicians. Owing in part to the relationship between the levels of Exhaled Nitric Oxide to inflammation and the ease of the technique, the measurement of the fraction of Exhaled Nitric Oxide (FENO) has achieved considerable attention, particularly with respect to asthma. A multitude of studies have shown that when measured in Exhaled air, this unique molecule has the potential to have both diagnostic and therapeutic roles in the clinical setting for many pulmonary diseases. The incorporation of FENO into asthma management and treatment algorithms may help shed further insight on the current control and future risk of patients. Research is ongoing to determine the biology and the benefits of the use of FENO in respiratory conditions in addition to asthma. This review will briefly outline the pathophysiology of Nitric Oxide, the measurement of FENO and the potential clinical uses of FEN...

Hiroyoshi Yoshinami - One of the best experts on this subject based on the ideXlab platform.

Seyyed Jalilmirmohammadi - One of the best experts on this subject based on the ideXlab platform.

  • The association between Exhaled Nitric Oxide and sleep apnea: the role of BMI.
    Respiratory medicine, 2014
    Co-Authors: Seyyed Jalilmirmohammadi, Amir Houshang Mehrparvar, Sara Safaei, Ehsan Samimi, Mona Torab Jahromi
    Abstract:

    Summary Background Obstructive sleep apnea syndrome is associated with airway inflammation. Measurement of Exhaled Nitric Oxide is a non-invasive method for evaluation of airway diseases. It seems that obesity is an exacerbating factor for airway inflammation. We aimed to evaluate the changes of Exhaled Nitric Oxide after sleep in patients suffering from OSA regarding BMI. Method In 54 patients referred for polysomnography, Exhaled Nitric Oxide measurements were performed before and after sleep. Subjects were divided into three categories: normal, obese with sleep apnea and non-obese, based on polysomnographic recordings and BMI. Results 47 subjects had abnormal apnea/hypopnea index (AHI mean = 39.7) and 7 were normal regarding AHI (AHI mean = 3.0). BMI was significantly correlated to AHI, number of desaturations and hypoxia. Among those with apnea, 31 subjects were obese and 16 were non-obese. Exhaled Nitric Oxide levels in normal and OSA subjects showed no significant change, but a significant increase was found in obese patients with apnea (14.7 pre-sleep mean, 20.0 post-sleep mean). Conclusions Obesity is an effective factor in the inflammation of airways in patients with obstructive apnea.